Bayer will not accept a ruling by the Intellectual Property Appellate Board in Chennai on Monday, upholding the compulsory licence granted on March 9 last year and it will appeal against the patent office order at the high court in Mumbai, a spokesperson told PTI.
The US Court of Appeals for the Federal Circuit has ruled in the company's favour regarding its appeal of a previous judgement by a lower court for Bayer AG's Yaz oral contraceptive product.
Multinational healthcare and pharmaceutical major Bayer Group said on Friday it is planning to sell its diagnostics business to Siemens AG, Germany for euro4.2 billion.
After being underweight on domestic agrochemical companies and preferring global plays, brokerages believe that the former may perform better in the quarters ahead. Domestic crop protection companies have faced multiple headwinds over the past year and a half, given high inventory costs, pricing pressures, lower realisations in the generic segment, increased stocks due to lower infestations, and demand-led hits to volumes. Some of the overhang from previous quarters was reflected in the April-June quarter (first quarter, or Q1) of 2023-24 (FY24) as well, with aggregate revenues and operating profit for the sector down 12 per cent and 27 per cent, respectively.
Zika virus outbreak in Brazil does not pose enough of a threat to warrant cancelling or putting off the Olympic Games set to be held in Rio de Janeiro in August, a leading US health official said.
Like pharmaceutical companies globally - which used to enjoy a preferential exchange rate in Venezuela - Indian producers have been left badly stung by the collapse of the bolivar currency
It could also ease the burden on the 225 million women in developing countries, says Ari Altstedter.
With monsoon rainfall 16% below the long-period average, total sowing area is down by 7% at 56.7 million hectares so far this season.
Delegation visit ahead of patent law report.
The environment ministry is likely to allow generic modification of food crops.
The Supreme Court had rejected the company's plea for a patent on cancer drug Glivec in April.
